Summary
Boston Scientific Corporation (BSX) reported a strong fiscal year 2023 with net sales reaching $14.24 billion, a 12.3% increase compared to 2022. This growth was driven by robust organic net sales growth of 12.3% and strategic acquisitions, demonstrating the company's diversified product portfolio and effective commercial execution across its MedSurg and Cardiovascular segments. Financially, the company reported a net income of $1.57 billion ($1.07 per diluted share) for 2023. On an adjusted basis, excluding certain charges and credits, adjusted net income was $3.00 billion ($2.05 per diluted share), highlighting operational improvements and strategic reinvestments. The company also strengthened its balance sheet, with significant operating cash flow and a healthy leverage ratio, positioning it well for future growth and strategic initiatives, including the pending acquisition of Axonics, Inc.
Financial Highlights
51 data points| Revenue | $14.24B |
| Cost of Revenue | $4.34B |
| Gross Profit | $9.90B |
| SG&A Expenses | $5.19B |
| Operating Expenses | $7.55B |
| Operating Income | $2.34B |
| Interest Expense | $265.00M |
| Net Income | $1.59B |
| EPS (Basic) | $1.08 |
| EPS (Diluted) | $1.07 |
| Shares Outstanding (Basic) | 1.45B |
| Shares Outstanding (Diluted) | 1.46B |
Key Highlights
- 1Net sales increased by 12.3% to $14.24 billion in 2023, driven by strong organic growth and strategic acquisitions.
- 2Reported net income was $1.57 billion, or $1.07 per diluted share, while adjusted net income was $3.00 billion, or $2.05 per diluted share.
- 3The company completed three significant acquisitions in 2023: Apollo Endosurgery, Inc., Relievant Medsystems, Inc., and a majority stake in Acotec Scientific Holdings Limited.
- 4The Cardiovascular segment, particularly Cardiology and Electrophysiology, showed strong performance, with net sales increasing by 13.1% and 12.6% respectively.
- 5MedSurg segment also demonstrated solid growth, with Endoscopy up 11.7% and Urology up 10.8%.
- 6Operating cash flow improved significantly, reaching $2.50 billion in 2023, compared to $1.53 billion in 2022.
- 7Boston Scientific announced a definitive agreement to acquire Axonics, Inc. for approximately $3.67 billion, expected to close in the first half of 2024, further enhancing its Urology portfolio.